Liminal BioSciences provides overview of priorities for CY23

Liminal BioSciences provided an overview of the company’s priorities for this calendar year. "We are thrilled to be starting the year with two promising early-stage programs, and the potential opportunities they bring for further development in 2023, along with a cash runway expected to support our near-term development plans," stated Bruce Pritchard, CEO. "We are nominating LMNL6511 as the lead preclinical drug candidate for our GPR84 Antagonist program, meeting another key milestone for the Company and strengthening our pipeline, bringing us closer to the clinic." The company said it finished 2022 with just over C$37M cash on hand, which is anticipated to support its near-term development goals into early 2024. Additionally, the company continues to actively seek opportunities to divest remaining non-core assets to reduce costs and to possibly further extend the cash runway.